Dual amylin and calcitonin receptor agonists and uses thereof
AssigneeEli Lilly and Company
InventorsTamer Coskun, Hongchang Qu
Life of this patent
Estimating the term…
Abstract
The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
Claims19
A method of treating a condition selected from the group consisting of diabetes, obesity, non-alcoholic steatohepatitis (NASH), and dyslipidemia, in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound comprising SEQ ID NO:
- 1 or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) receptor agonist.
A method of treating a condition selected from the group consisting of diabetes, obesity, NASH, and dyslipidemia, in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound comprising SEQ ID NO:
- 1 or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a dual agonist of GLP-1 and gastric inhibitory peptide (GIP) receptors.
A method of treating a condition selected from the group consisting of diabetes, obesity, NASH, and dyslipidemia, in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound comprising SEQ ID NO:
- 1 or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a tri-agonist of glucagon, GIP, and GLP-1 receptors.
A method of treating a condition selected from the group consisting of diabetes, obesity, NASH, and dyslipidemia, in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound comprising SEQ ID NO:
- 1 or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of an analog of oxyntomodulin.
Dependencies are inferred from the claim text.